Company Analysis

Akari Therapeutics plc (AKTX)

Nasdaq: AKTX · Pharmaceutical Preparations · Tampa, FL · filing with the SEC since 2012
Grade3.5
◀ Past 3.4● Present 3.0▶ Future 3.8
6 est.

Who runs Akari Therapeutics plc

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Gaslightwala Abizer
CEO. First filing Dec 2024, latest Oct 16, 2026, 4 filings in all.
Officers reporting now
3
of 9 people with a filing in the last fifteen months
Directors reporting now
6
21 people on the record since 2015
Officerssales are open-market, Oct 16, 2025 to Oct 16, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Gaslightwala AbizerCEODec 2024Oct 16, 2026none
Vat-Ho VatnakChief Business OfficerOct 2026Oct 14, 2026none
Farag Kameel D.Interim CFOOct 2025Aug 19, 2026none
Directorssales are open-market, Oct 16, 2025 to Oct 16, 2026
NameRoleFirst filingLatest filingSales, 12 months
Bazemore Robert BdirectorSep 2024Oct 16, 2026none
Huh HoyoungdirectorNov 2024Oct 16, 2026none
Patel Samir RashmikantdirectorJan 2024Oct 16, 2026none
Patel Sandip IdirectorNov 2024Oct 16, 2026none
Prudo-Chlebosz RaymonddirectorSep 2015Oct 16, 2026none
Neal James RdirectorNov 2024Mar 16, 2026none
Earlier names on the record12, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton AKTX · research, not advice